GlaxoSmithKline PLC (GSK) to Post Q3 2017 Earnings of $0.86 Per Share, Jefferies Group Forecasts

GlaxoSmithKline PLC (NYSE:GSK) – Investment analysts at Jefferies Group issued their Q3 2017 EPS estimates for GlaxoSmithKline PLC in a report issued on Tuesday. Jefferies Group analyst J. Holford expects that the pharmaceutical company will earn $0.86 per share for the quarter. Jefferies Group also issued estimates for GlaxoSmithKline PLC’s FY2017 earnings at $2.98 EPS and FY2018 earnings at $2.87 EPS.

Other analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 target price for the company in a report on Tuesday, July 18th. Argus restated a “buy” rating and issued a $50.00 price target on shares of GlaxoSmithKline PLC in a research report on Thursday, August 31st. TheStreet downgraded shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, September 21st. Finally, Citigroup Inc. downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 5th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $44.33.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Week Herald and is the sole property of of Week Herald. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://weekherald.com/2017/10/20/glaxosmithkline-plc-gsk-to-post-q3-2017-earnings-of-0-86-per-share-jefferies-group-forecasts.html.

GlaxoSmithKline PLC (GSK) opened at 41.10 on Wednesday. GlaxoSmithKline PLC has a 12 month low of $37.20 and a 12 month high of $44.54. The company’s 50 day moving average price is $40.50 and its 200 day moving average price is $41.54. The firm has a market capitalization of $100.45 billion, a P/E ratio of 39.83 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last issued its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The firm had revenue of $9.36 billion during the quarter, compared to the consensus estimate of $9.52 billion.

The business also recently announced a quarterly dividend, which was paid on Thursday, October 12th. Shareholders of record on Friday, August 11th were given a $0.491 dividend. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend was Wednesday, August 9th. This represents a $1.96 dividend on an annualized basis and a yield of 4.78%. GlaxoSmithKline PLC’s dividend payout ratio is presently 198.00%.

A number of hedge funds have recently added to or reduced their stakes in the business. 1st Global Advisors Inc. lifted its position in GlaxoSmithKline PLC by 0.4% in the 2nd quarter. 1st Global Advisors Inc. now owns 5,271 shares of the pharmaceutical company’s stock worth $227,000 after buying an additional 19 shares in the last quarter. Carroll Financial Associates Inc. lifted its position in GlaxoSmithKline PLC by 0.4% in the 2nd quarter. Carroll Financial Associates Inc. now owns 8,690 shares of the pharmaceutical company’s stock worth $374,000 after buying an additional 35 shares in the last quarter. King Luther Capital Management Corp lifted its position in GlaxoSmithKline PLC by 1.0% in the 2nd quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock worth $234,000 after buying an additional 55 shares in the last quarter. First National Bank of Omaha lifted its position in GlaxoSmithKline PLC by 0.3% in the 2nd quarter. First National Bank of Omaha now owns 19,177 shares of the pharmaceutical company’s stock worth $827,000 after buying an additional 57 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its position in GlaxoSmithKline PLC by 1.9% in the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock worth $137,000 after buying an additional 64 shares in the last quarter. Institutional investors own 9.28% of the company’s stock.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Earnings History and Estimates for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply